Cited 14 times in
Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김상운 | - |
dc.contributor.author | 김성훈 | - |
dc.contributor.author | 김영태 | - |
dc.contributor.author | 김재훈 | - |
dc.contributor.author | 남은지 | - |
dc.contributor.author | 장시영 | - |
dc.date.accessioned | 2015-04-23T16:45:57Z | - |
dc.date.available | 2015-04-23T16:45:57Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0277-3732 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101183 | - |
dc.description.abstract | OBJECTIVE: This study was performed to determine the safety and efficacy of belotecan, a new camptothecin analogue and potent topoisomerase I inhibitor, with and without platinum in patients with recurrent ovarian cancer. METHODS: Fifty-three patients with recurrent or persistent ovarian cancer were enrolled between March 2005 and March 2008. Eligible patients received 0.5 mg/m of intravenous (IV) belotecan on days 1 to 5, every 3 weeks belotecan monotherapy (B) or 50 mg/m of IV cisplatin on day 1 plus 0.3 mg/m of IV belotecan on days 1 to 5, every 3 weeks (belotecan plus cisplatin combination therapy [BP]). RESULTS: Of the 53 treated patients, 34 received BP and 19 received B. Thirty-four patients had platinum-sensitive (PS) disease and 19 had platinum-resistant disease. The overall response of the 53 patients was 37.7% (20/53). According to regimen, the response rate in the BP group was 47.1% (16/34) and that of the B group was 21.1% (4/19). BP had better response (66.7%, 14/21) than B (15.4%, 2/13) for PS disease (P = 0.004), but it was not superior in terms of progression-free survival (BP, 6 month; B, 7 months). Grade 3 or 4 toxicity was less common in B than in BP. CONCLUSION: Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer. These results warrant further prospective randomized trials. Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 233~237 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents, Phytogenic/therapeutic use* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Camptothecin/administration & dosage | - |
dc.subject.MESH | Camptothecin/analogs & derivatives* | - |
dc.subject.MESH | Camptothecin/therapeutic use | - |
dc.subject.MESH | Carcinoma/drug therapy* | - |
dc.subject.MESH | Carcinoma/mortality | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Drug Resistance, Neoplasm | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hematologic Diseases/chemically induced | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Recurrence, Local/drug therapy | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Ovarian Neoplasms/drug therapy* | - |
dc.subject.MESH | Ovarian Neoplasms/mortality | - |
dc.subject.MESH | Salvage Therapy | - |
dc.subject.MESH | Survival Analysis | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics & Gynecology (산부인과학) | - |
dc.contributor.googleauthor | Eun Ji Nam | - |
dc.contributor.googleauthor | Jae Wook Kim | - |
dc.contributor.googleauthor | Jae Hoon Kim | - |
dc.contributor.googleauthor | Sunghoon Kim | - |
dc.contributor.googleauthor | Sang Wun Kim | - |
dc.contributor.googleauthor | Si Young Jang | - |
dc.contributor.googleauthor | Dae Woo Lee | - |
dc.contributor.googleauthor | Yong Wook Jung | - |
dc.contributor.googleauthor | Young Tae Kim | - |
dc.identifier.doi | 10.1097/COC.0b013e3181a650bc | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00526 | - |
dc.contributor.localId | A00729 | - |
dc.contributor.localId | A00876 | - |
dc.contributor.localId | A01262 | - |
dc.contributor.localId | A03447 | - |
dc.contributor.localId | A00595 | - |
dc.relation.journalcode | J00075 | - |
dc.identifier.eissn | 1537-453X | - |
dc.identifier.pmid | 19745693 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00000421-201006000-00004&LSLINK=80&D=ovft | - |
dc.contributor.alternativeName | Kim, Sang Wun | - |
dc.contributor.alternativeName | Kim, Sung Hoon | - |
dc.contributor.alternativeName | Kim, Young Tae | - |
dc.contributor.alternativeName | Kim, Jae Hoon | - |
dc.contributor.alternativeName | Nam, Eun Ji | - |
dc.contributor.alternativeName | Jang, Si Young | - |
dc.contributor.affiliatedAuthor | Kim, Sang Wun | - |
dc.contributor.affiliatedAuthor | Kim, Young Tae | - |
dc.contributor.affiliatedAuthor | Kim, Jae Hoon | - |
dc.contributor.affiliatedAuthor | Nam, Eun Ji | - |
dc.contributor.affiliatedAuthor | Jang, Si Young | - |
dc.contributor.affiliatedAuthor | Kim, Sung Hoon | - |
dc.citation.volume | 33 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 233 | - |
dc.citation.endPage | 237 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, Vol.33(3) : 233-237, 2010 | - |
dc.identifier.rimsid | 52118 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.